3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...
Vertex Pharmaceuticals EVP Edward Atkinson sold 1,767 shares for $849,838 on Feb. 25, 2025. This transaction, conducted under ...
Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...
Vertex Pharmaceuticals has been attracting investor attention due to strong recent stock performance. The company's shares ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Zacks.com on MSN2d
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowVertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...
Vertex Pharmaceuticals Incorporated Investors: [email protected] Susie Lisa, CFA: +1 617-341-6108 or Miroslava Minkova: +1 617-341-6135 Media: [email protected] or International: +44 20 3204 ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback